NASDAQ:NXTC NextCure Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NextCure Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.29 -0.09 (-1.07 %) (As of 09/28/2020 12:00 AM ET) Add Compare Share Today's Range$8.06Now: $8.29▼$8.5050-Day Range$8.21MA: $9.05▼$10.0452-Week Range$7.91Now: $8.29▼$109.00Volume303,966 shsAverage Volume473,450 shsMarket Capitalization$228.12 millionP/E RatioN/ADividend YieldN/ABeta-0.55 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media There is no company description available for NextCure Inc.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingNextCure has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.70, NextCure has a forecasted upside of 294.5% from its current price of $8.29.Amount of Analyst CoverageNextCure has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesNextCure has received 56 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNextCure has received 47 “underperform” votes. (Add your “underperform” vote.)Community SentimentNextCure has received 54.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote “Outperform” if you believe NXTC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.05% of the stock of NextCure is held by insiders.Percentage Held by Institutions73.59% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NextCure are expected to decrease in the coming year, from ($1.31) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NXTC Previous Symbol CUSIPN/A CIKN/A Webwww.nextcure.com Phone240-399-4900Debt Debt-to-Equity Ratio0.01 Current Ratio37.68 Quick Ratio37.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.35 million Price / Sales35.92 Cash FlowN/A Price / Cash FlowN/A Book Value$14.13 per share Price / Book0.59Profitability EPS (Most Recent Fiscal Year)($2.15) Net Income$-33,740,000.00 Net Margins-65.22% Return on Equity-8.43% Return on Assets-7.80%Miscellaneous EmployeesN/A Outstanding Shares27,517,000Market Cap$228.12 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $8.29 -0.09 (-1.07 %) (As of 09/28/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NXTC News and Ratings via Email Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. NextCure (NASDAQ:NXTC) Frequently Asked Questions How has NextCure's stock price been impacted by COVID-19 (Coronavirus)? NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 78.3% and is now trading at $8.29. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of NextCure? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for NextCure. When is NextCure's next earnings date? NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for NextCure. How were NextCure's earnings last quarter? NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.03. NextCure had a negative net margin of 65.22% and a negative return on equity of 8.43%. View NextCure's earnings history. What price target have analysts set for NXTC? 9 brokers have issued twelve-month target prices for NextCure's shares. Their forecasts range from $11.00 to $87.00. On average, they anticipate NextCure's share price to reach $32.70 in the next twelve months. This suggests a possible upside of 294.5% from the stock's current price. View analysts' price targets for NextCure. Are investors shorting NextCure? NextCure saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,970,000 shares, an increase of 8.8% from the August 15th total of 1,810,000 shares. Based on an average daily volume of 857,800 shares, the days-to-cover ratio is presently 2.3 days. Approximately 12.1% of the shares of the stock are short sold. View NextCure's Short Interest. Who are some of NextCure's key competitors? Some companies that are related to NextCure include Arvinas (ARVN), Vectura Group (VEGPF), Enanta Pharmaceuticals (ENTA), Amphastar Pharmaceuticals (AMPH), Morphic (MORF), Passage Bio (KROS), Akouos (AKUS), Pliant Therapeutics (PLRX), Protagonist Therapeutics (PTGX), Endo International (ENDP), Phibro Animal Health (PAHC), RAPT Therapeutics (RAPT), Provention Bio (PRVB), VBI Vaccines (VBIV) and Emisphere Technologies (EMIS). View all competitors. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Kadmon (KDMN), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT). When did NextCure IPO? (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO. What is NextCure's stock symbol? NextCure trades on the NASDAQ under the ticker symbol "NXTC." Who are NextCure's major shareholders? NextCure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (3.63%), Cormorant Asset Management LP (2.52%), Hillhouse Capital Advisors LTD. (2.32%), Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%) and Federated Hermes Inc. (0.41%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View institutional ownership trends for NextCure. Which major investors are selling NextCure stock? NXTC stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Great Point Partners LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cormorant Asset Management LP, and Nuveen Asset Management LLC. View insider buying and selling activity for NextCure. Which major investors are buying NextCure stock? NXTC stock was bought by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Federated Hermes Inc., Point72 Asset Management L.P., Asymmetry Capital Management L.P., Two Sigma Advisers LP, SG Americas Securities LLC, Swiss National Bank, and Vident Investment Advisory LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan. View insider buying and selling activity for NextCure. How do I buy shares of NextCure? Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NextCure's stock price today? One share of NXTC stock can currently be purchased for approximately $8.29. How big of a company is NextCure? NextCure has a market capitalization of $228.12 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. What is NextCure's official website? The official website for NextCure is www.nextcure.com. How can I contact NextCure? NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
